eClinical Technology and Industy News

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

-FLX475-treated patients exhibited significant changes in immune pathways likely to enhance an antitumor response

-FLX475 modifies the tumor microenvironment (TME) to resemble those of responders to anti-PD(L)1 monotherapy

Excerpt from the Press Release:

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced biomarker data for FLX475 from its ongoing FLX475-02 Phase 1/2 clinical trial which corroborate the clinical activity of FLX475 reported in Epstein-Barr virus-positive (EBV+) lymphoma, EBV+ gastric cancer and non-small cell lung cancer (NSCLC), as well as the mechanism of this novel CCR4 antagonist. These data will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place next week at the McCormick Place Convention Center in Chicago, IL.

FLX475 is a potent and selective CCR4 antagonist, designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into tumors without affecting healthy tissues. In December 2022 at ESMO-IO, a clinical update from the Phase 1/2 trial reported evidence of monotherapy and combination activity. FLX475 monotherapy induced confirmed complete metabolic responses in two of the six evaluable patients with EBV+ NK/T cell lymphoma. In patients with checkpoint inhibitor naïve NSCLC, the overall confirmed objective response rate was 31% (4/13 patients), and the confirmed objective response rate in PD-L1+ tumors was 38% (3/8 patients) following treatment with FLX475 plus pembrolizumab.

As part of the clinical trial protocol, the company analyzed peripheral blood and tumor tissue biomarker data from patients with a broad range of tumor types treated with FLX475 monotherapy.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?